Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13438130 | 0.82 | TKT (0.43) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL2612158 | 0.80 | GAA (0.40) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL2725034 | 0.77 | KDM4E (0.37) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL13184316 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL14938067 | 0.77 | KDM4E (0.32) | KDM4EADORA2AADORA2BGAA | |
| SCHEMBL972069 | 0.76 | KDM4E (0.34) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL14496271 | 0.76 | GAA (0.33) | KDM4EALDH1A1ADORA2AADORA2BGAA | |
| SCHEMBL20138037 | 0.76 | — | — | |
| SCHEMBL972904 | 0.76 | GAA (0.35) | KDM4EADORA2AADORA2BGAA | |
| SCHEMBL25944182 | 0.76 | ADORA2A (0.32) | KDM4EADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | STS, NAPA, NAAA | KDM4E 3294/4885ALDH1A1 2768/4885ADORA2A 2148/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | KDM4E 1906/4885ALDH1A1 2393/4885ADORA2A 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.